Key facts
- CYGENTA (China)’s last known valuation is $16.9M (Oct 2022).
- Notable investors include Innoangel Fund, SJ Jiacheng Investment Management, Lhasa Anchao Investment Management, Momentum Venture, SAFE Pharmaceutical — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for CYGENTA (China)
- ·The full record, as it builds
Funding rounds
No funding rounds for CYGENTA (China) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CYGENTA (China)
Provider of contract development and manufacturing services designed for cell and gene therapy applications. The company offers a full-process service platform encompassing early development, investigational new drug (IND) registration, clinical trials, and commercialization, with capabilities in plasmid production, viral vector manufacturing, cell processing, and comprehensive quality control analysis; enabling biotechnology and pharmaceutical companies to streamline the development and production of advanced therapeutic products.
- Sector
- Business Products and Services (B2B)
- HQ
- Beijing, China
- Founded
- 2022
- Website
- cgtcdmo.com/
- Ownership
- Privately Held (backing)
CYGENTA (China) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CYGENTA (China) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CYGENTA (China) in its N-PORT filings yet. We sweep new filings monthly.